Pancreatitis Associated with the use of Sitagliptin and Orlistat combination: A case report

Garg, Ranjna; Ibrahim, Siti Fatimah; Hussey, Christine

doi:10.1111/j.1464-5491.2009.02950.x

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This patient's score was 6, meaning that it is probable that linagliptin was the cause of acute pancreatitis in this patient (11). Other case reports of DPP-4 inhibitor-induced pancreatitis have mentioned a period of time between 12 weeks and 8 months from the first administration of the drug to the appearance of symptoms (5,6). These findings are consistent with the time frame in which our patient presented her symptoms.…”

Section: Discussionsupporting

confidence: 89%

“…Additionally, a combined analysis of 3 large interventional trials using DPP-4 inhibitors published in 2017 showed a slight but significant increase in the incidence of acute pancreatitis (4). In the English medical literature there have been case reports associating sitagliptin with acute pancreatitis (5,6). In 2018, the first case report associating linagliptin with acute pancreatitis was published (7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Linagliptin-Induced Pancreatitis

Mosquera

Torres

Restrepo

et al. 2020

AACE Clinical Case Reports

View full text Add to dashboard Cite

Objective: To report a case of linagliptin-induced acute pancreatitis and remind clinicians about risks with incretin-based drugs. Patients at risk for pancreatitis should be switched to another type of hypoglycemic treatment. Methods: We present the case of a 74-year-old Latina who presented to the emergency department with sudden onset of epigastric pain radiating to her back. Medical history, physical exam, laboratory tests, and medical images were compatible with acute pancreatitis. Upon further investigation, common causes for her pathology were excluded. Ten weeks prior to presentation she had changed her medications for diabetes mellitus type 2 to linagliptin. Results: Using the Naranjo algorithm of adverse drug reactions, we concluded that linagliptin was the most likely culprit. Conclusion: Incretin-based drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, have been shown to be relatively safe for the management of type 2 diabetes mellitus. Since their introduction to the market, conflicting data regarding pancreatic side effects have been published, including a small risk of developing acute pancreatitis with dipeptidyl peptidase-4 inhibitors like sitagliptin and saxagliptin. To date there has been only 1 case report associating linagliptin with acute pancreatitis in the English medical literature. Ours is the first case report in the United States associating linagliptin with acute pancreatitis. It is worth warning both patients and prescribers about this serious adverse effect, as it might affect the choice of antiglycemic agent.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Linagliptin-Induced Pancreatitis

Mosquera

Torres

Restrepo

et al. 2020

AACE Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…There have been six published case reports of pancreatitis attributed to GLP‐1‐dependent diabetic therapies, including DPP‐IV inhibitors as well as synthetic GLP‐1 receptor agonists such as exenatide . In response to pancreatitis reported in post‐marketing surveillance through the Adverse Event Reporting System (AERS), the FDA has issued revised prescribing information for sitagliptin stating that cases of acute pancreatitis have been reported with use, to monitor closely for signs and symptoms of pancreatitis, and to use sitagliptin with caution in patients with a history of pancreatitis .…”

Section: Discussionmentioning

confidence: 99%

Sitagliptin‐induced pancreatitis – a longer road than expected

Nelson

Bhandari

Wener

2014

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…In the literature, there are seven previously reported cases of acute pancreatitis in patients receiving DPP-4 inhibitors (Table) (5)(6)(7)(8)(9)(10)(11). Although the DPP-4 inhibitors, sitagliptin and vildagliptin, were suspected by the authors to be the triggering factors for acute pancreatitis, common risk factors, such as gallstones or mild hypertriglyceridemia, were also present in some cases.…”

Section: Discussionmentioning

confidence: 99%

“…Thereafter, several large retrospective studies investigating the causal relationship between the administration of incretin-based therapy and acute pancreatitis showed conflicting results (2)(3)(4). However, cases of acute pancreatitis associated with treatment with glucagon-like peptide-1 (GLP-1) agonists or DPP-4 inhibitors continue to be reported worldwide (5)(6)(7)(8)(9)(10)(11). Among the DPP-4 inhibitors, the suspected offending drugs include sitagliptin and vildagliptin.…”

Section: Introductionmentioning

confidence: 99%

Saxagliptin-induced Recurrent Acute Pancreatitis

2014

View full text Add to dashboard Cite

Although dipeptidyl peptidase-4 (DPP-4) inhibitors have been implicated in the development of acute pancreatitis, the causality of this phenomenon is not well established. We herein report the case of an 85-yearold woman who presented with epigastric pain after taking saxagliptin for five months. A high serum lipase level with characteristic computed tomography findings confirmed the diagnosis of acute pancreatitis. The patient's symptoms rapidly resolved after admission, although they recurred when she resumed treatment with saxagliptin for 18 days after discharge. In the absence of any identifiable causes of pancreatitis and considering the temporal sequence of events, the saxagliptin therapy was highly suspected to be the triggering factor. Although drug-induced pancreatitis is rare, treatment with DPP-4 inhibitors should be included as a potential etiology of acute pancreatitis.

show abstract

Pancreatitis Associated with the use of Sitagliptin and Orlistat combination: A case report

Cited by 4 publications

References 0 publications

Linagliptin-Induced Pancreatitis

Linagliptin-Induced Pancreatitis

Sitagliptin‐induced pancreatitis – a longer road than expected

Saxagliptin-induced Recurrent Acute Pancreatitis

Contact Info

Product

Resources

About